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ORIGINAL ARTICLE
A growth hormone receptor SNP promotes lung cancer
by impairment of SOCS2-mediated degradation
Y Chhabra1,2, HY Wong3, LF Nikolajsen4, H Steinocher4, A Papadopulos5, KA Tunny1,2, FA Meunier5, AG Smith6, BB Kragelund4,
AJ Brooks1,2,7 and MJ Waters1,7
Both humans and mice lacking functional growth hormone (GH) receptors are known to be resistant to cancer. Further, autocrine
GH has been reported to act as a cancer promoter. Here we present the ﬁrst example of a variant of the GH receptor (GHR)
associated with cancer promotion, in this case lung cancer. We show that the GHRP495T variant located in the receptor intracellular
domain is able to prolong the GH signal in vitro using stably expressing mouse pro-B-cell and human lung cell lines. This is relevant
because GH secretion is pulsatile, and extending the signal duration makes it resemble autocrine GH action. Signal duration for the
activated GHR is primarily controlled by suppressor of cytokine signalling 2 (SOCS2), the substrate recognition component of the E3
protein ligase responsible for ubiquitinylation and degradation of the GHR. SOCS2 is induced by a GH pulse and we show that
SOCS2 binding to the GHR is impaired by a threonine substitution at Pro 495. This results in decreased internalisation and
degradation of the receptor evident in TIRF microscopy and by measurement of mature (surface) receptor expression. Mutational
analysis showed that the residue at position 495 impairs SOCS2 binding only when a threonine is present, consistent with
interference with the adjacent Thr494. The latter is key for SOCS2 binding, together with nearby Tyr487, which must be
phosphorylated for SOCS2 binding. We also undertook nuclear magnetic resonance spectroscopy approach for structural
comparison of the SOCS2 binding scaffold Ile455-Ser588, and concluded that this single substitution has altered the structure of the
SOCS2 binding site. Importantly, we ﬁnd that lung BEAS-2B cells expressing GHRP495T display increased expression of transcripts
associated with tumour proliferation, epithelial–mesenchymal transition and metastases (TWIST1, SNAI2, EGFR, MYC and CCND1) at
2 h after a GH pulse. This is consistent with prolonged GH signalling acting to promote cancer progression in lung cancer.
Oncogene advance online publication, 2 October 2017; doi:10.1038/onc.2017.352
INTRODUCTION
Considerable evidence supports a role for the growth hormone
(GH)–insulin-like growth factor-1 (IGF-1) axis in cancer incidence
and progression.1 This includes epidemiological studies linking
elevated circulating IGF-1 to increased colorectal, breast, prostate
and lung cancer incidences.2–4 Conversely, an absence of cancer
has been reported in humans harbouring a GH receptor (GHR)
mutation resulting in IGF-1 deﬁciency.5 Moreover, rodent models
lacking GH or its cognate receptor (GHR) are strikingly resistant to
the induction and severity of a wide range of cancers,6 and
treatment with pegvisomant (GHR antagonist) can slow tumour
progression.7 Although expression of GHR is elevated in many
cancers such as primary ductal invasive breast cancer,2 autocrine
GH is present in several cancer types and predicts a worse
outcome of mammary and endometrial cancers.8 Forced expres-
sion of autocrine GH has been shown to induce cell
transformation.9
Two independent studies showed that a single-nucleotide
polymorphism (SNP) in GHR (C to A on GHR1526; rs6183) resulting
in an amino-acid change at position 495 from proline to threonine
(P495T) was associated with lung cancer. A genome-wide
association study (GWAS) identiﬁed GHRP495T with a striking
odds ratio (OR) of 12.98 in a Caucasian population of smokers
(94%).10 The other report, a comprehensive study in a Han Chinese
population, showed that GHRP495T was associated with lung
cancer with an OR of 2.04.11 This latter study showed that
GHRP495T was strongly associated with lung cancer in the sub-
populations with higher risk for lung cancer (males, still-smokers,
and the sub-population with familial history of cancer), was
signiﬁcantly associated with small cell and squamous cell lung
cancer, and was proposed to carry a familial risk for these cancers.
A recent SNP analysis of non-small cell lung cancer (NSCLC) in a
population-based study of women comparing Caucasians and
African-Americans identiﬁed three other SNPs in linkage disequili-
brium with GHRP495T that associated with a 50% increased cancer
risk and indicated that the disease marker could well be
GHRP495T. This study also conﬁrmed the association of SNPs in
this region of GHR with smoking.12
There is currently no functional role attributed to GHR P495,
however, Y487 is phosphorylated (pY487) upon GHR activation
and this forms a known binding site for signal transducer and
activator of transcription 5 (STAT5) and for suppressor of cytokine
1Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia; 2The University of Queensland Diamantina Institute, The University of
Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia; 3University of Queensland Centre for Clinical Research, The University of Queensland,
Herston, Queensland, Australia; 4Structural Biology and NMR Laboratory (SBiNLab), Department of Biology, University of Copenhagen, Copenhagen, Denmark; 5The Clem Jones
Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia and 6School of Biomedical Sciences, Institute of
Health and Biomedical Innovation at the Translational Research Institute, Queensland University of Technology, Woolloongabba, Queensland, Australia. Correspondence:
Dr AJ Brooks, The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.
E-mail: a.brooks@uq.edu.au
7Shared senior authorship.
Received 23 February 2017; revised 13 August 2017; accepted 16 August 2017
Oncogene (2017), 1–13
www.nature.com/onc
signalling 2 (SOCS2),13 a ubiquitin ligase negatively regulating GHR
expression and downstream JAK2/STAT5 signalling.14 SOCS
protein levels are constitutively low, but their expression increases
rapidly following cytokine stimulation.15 GH induces the expres-
sion of several SOCS proteins in vitro16,17 and in vivo.18 Generally,
SOCS1, SOCS3 and cytokine-inducible SH2-containing protein
(CISH) expression is rapidly induced following GH stimulation, but
is short-lived, whereas SOCS2 expression increases steadily with
time.19 There is evidence that binding to pY487 and pY595 is
required for SOCS2-mediated inhibition on GH action.20 As both
tyrosines are known STAT5 binding sites, SOCS2 can competitively
inhibit STAT5 receptor binding.21,22 Recently, pY487 rather than
pY595 was assigned the key role for regulation by SOCS2, and it
was further shown that SOCS2 regulates cellular GHR levels
through ubiquitinylation-dependent proteasomal degradation.13
Importantly, of SOCS proteins, only SOCS2 knockout mice show a
signiﬁcant increase in size (~40%) compared with wild-type
mice.23 This supports the key role of SOCS2 in GHR signalling.
Accordingly, to elucidate the role of the GHRP495T in lung cancer
promotion, we have investigated the effect of the P495T
substitution on GHR structure, signalling and regulation by SOCS2
activity.
RESULTS
GHR expression in normal and cancerous lung tissue
Analysis of a gene expression microarray GEO data set for GHR
transcript levels comparing 18 squamous cell carcinoma (SCC) and
40 lung adenocarcinoma tissues (GSE10245)24 showed higher GHR
levels in SCC than in adenocarcinoma (Figure 1a). This is consistent
with the GHRP495T variant being signiﬁcantly associated with
small cell and SCC, but not with adenocarcinoma. To further
investigate relative expression levels in a NSCLC cohort, bio-
informatics analysis (GSE19804)25 of transcript levels in clinical
samples from 60 normal lung tissues and 60 NSCLC tumours from
non-smoking females was performed. There was signiﬁcantly
higher GHR and EGFR expression in NSCLC (Figures 1b and c), with
a relative decrease in SOCS2 and SOCS3 levels in NSCLC
(Figures 1d and e) but no evident difference in SOCS1, CISH, and
GH2 transcript levels (Supplementary Figure 1).
The GHRP495T enhances GH-mediated signalling
We ﬁrst compared proliferative signalling in Ba/F3 cells transduced
to express human GHRP495T or wild-type (WT) GHR in Ba/F3, with
surface receptor levels matched by ﬂuorescence-activated cell
sorting using an N-terminal HA-tag. Although no constitutive
activation was evident in the GHRP495T, cell proliferation was
signiﬁcantly increased in response to 4.5 nM human GH (hGH)
(Figure 2a). GH secretion is highly pulsatile in males, with
somewhat lower amplitude pulses in females,26–28 thus starved
cells were stimulated with 2.3 nM hGH for 15 min, then washed,
and a cell fraction harvested at subsequent time intervals. At 90–
150 min after the GH pulse, phosphorylated STAT5, the major
effector of GH-induced proliferation in these cells, was signiﬁcantly
increased for GHRP495T relative to WT GHR cells (normalised to β-
TUBULIN) and relative to GHR levels (Figures 2b and c). When we
investigated multiple transduced and selected cell lines based on
ﬂuorescence-activated cell sorting for equal surface GHR, each
time the GHRP495T gave elevated total GHR levels compared with
WT GHR in the absence of GH (Figure 2b). We attributed this to the
reduced degradation/turnover of the GHRP495T within the cell
compared with WT GHR cells. In the absence of any exogenous
hGH, no STAT5 activation was evident as murine GH (poorly
expressed in Ba/F3 cells) and bovine GH (small amounts present in
the serum) do not activate human GHR.29,30
We next examined GH signalling in a non-tumourigenic human
bronchial epithelial lung cell line (BEAS-2B) transduced to express
matched levels of WT GHR or GHRP495T. Proliferation was
enhanced in GHRP495T cells in response to 2.3 nM and 4.5 nM
hGH (Figure 3a) based on BrdU incorporation. Signalling in
response to a GH pulse showed that AKT signalling (measured by
AKT pT308) increased signiﬁcantly in GHRP495T cells from 45 min
after the GH pulse (Figures 3b and c). AKT-T308 phosphorylation is
a strong prognostic indicator for NSCLC.31 Similarly, phospho-
STAT3 levels (pY705) were signiﬁcantly elevated 45–60 min after
the GH pulse (Figures 3d and e). Activated STAT3 is an important
oncogenic factor during carcinogenesis and metastasis of SCLC
and squamous cell lung carcinoma, and correlates with clinical
stage, prognosis, and lymph node metastasis,32 as well as smoking
history.33
The GHRP495T impairs SOCS2 binding
No difference was found between the ability of HEK293 cells
expressing WT GHR or GHRP495T to induce SOCS2 transcript upon
GH stimulation (Figure 4a). However, co-immunoprecipitation (co-
IP) analysis of SOCS2 with WT GHR or GHRP495T demonstrated
that SOCS2 binding to the activated GHRP495T receptor was
markedly impaired (Figures 4b and c). No signiﬁcant interaction
between CISH and WT GHR was observed (Figure 4d), consistent
with the in vivo situation where in hepatic tissue derived from WT
mice we observed continuous turnover of SOCS2, but not CISH
(Supplementary Figure 2). As expected, a decline in socs2 and cish
transcript levels was observed in ghr-/- mice because of lack of
GHR-activated STAT5. In contrast, SOCS2 protein levels were high,
whereas no difference in CISH protein level was observed
between ghr-/- and WT mice. This result is consistent with
impaired turnover of SOCS2 because of the lack of GHR-mediated
proteolysis, whereas CISH was unaffected because of its lack of
direct interaction with GHR.
Mutational analysis of SOCS2 binding to GHR
To investigate the conservation of the GHR P495 and the
surrounding residues, we performed a Clustal Omega alignment
with other species and identiﬁed P495 and residues in close
proximity to be highly conserved (Figure 5a). Mutational analysis
of these conserved residues revealed that alanine or lysine
substitution of P495 did not signiﬁcantly alter SOCS2 binding to
GHR, however, substitution of the adjacent T494 with alanine
strongly impaired its binding (Figures 5b and c).
GHRP495T causes structural changes in the intracellular domain
We used nuclear magnetic resonance spectroscopy to deﬁne the
structural propensity of the WT GHR and GHRP495T using the
intracellular region of the receptor spanning I455-S588. We
recently reported that the cytoplasmic domain is intrinsically
disordered, but with eight 10–30% transiently populated helices
(THs).34 Compared with other amino acids, proline gives
conformational rigidity. P495 resides between TH5.2 and TH6,
and has no helical propensity. Mutation to threonine induced a
new transient structure, TH5.3 with effects also on TH5.2
(Figure 5d). This change in the structural ensemble could bring
T495 closer to Y487 and within proximity of the key arginine
residues of SOCS2 causing steric hindrance/interference. More-
over, increased helicity around Y487 may put I484 and V490 (i-3, i
+3), both SOCS2 speciﬁcity residues, in an orientation facing away
from Y487, which may add to reduce binding efﬁciency to SOCS2
that relies on intrinsic disorder and formation of extended
structure.35,36
GHRP495T degradation is impaired
We studied the effect of GHRP495T on receptor turnover with and
without co-transfection of SOCS2. HEK293 cells were pre-treated
with Brefeldin A (BFA) (1 μg/ml) to block incorporation of new
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receptor into the plasma membrane, followed by a 15-min GH
pulse, and followed the rate of disappearance of the mature
(upper) GHR band in immunoblots. Degradation of the mature
surface GHRP495T was signiﬁcantly less than WT GHR in response
to GH (Figures 6a and b) and this effect was exacerbated by
transfection of a SOCS2 expression plasmid (Figures 6c and d).
A time course assay was performed in BEAS-2B cells with a
second dose of GH at 60 and 120 min; time points where the
levels of mature GHR were very different between WT GHR and
GHRP495T (Figure 3b). Following the second acute GH stimulation,
GHRP495T was clearly less prone to degradation than WT GHR
(Supplementary Figure 3).
In order to investigate surface GHR, HEK293 cells transduced to
stably express WT or GHRP495T each with a C-terminal fusion to
GFP were transiently transfected with a SOCS2-mCherry
expression plasmid. The presence of both SOCS2 and GHRP495T
at the basal plasma membrane of the GHRP495T-expressing cells
was clearly observed by TIRF microscopy, but not for WT GHR
where it was largely absent in the presence of SOCS2-mCherry
(Figure 6e). Quantitation of these observations showed a
signiﬁcant decrease in WT GHR at the basal plasma membrane
in the presence of SOCS2, but not for the GHRP495T receptor
(Figure 6f), whereas SOCS2 ﬂuorescence showed no difference in
its plasma membrane level between WT and GHRP495T
(Figure 6g). Co-IP analysis showed no difference in SOCS2 binding
between GFP-tagged and non-GFP-tagged WT GHR
(Supplementary Figure 4), demonstrating that SOCS2 interaction
was unaffected by GFP-fusion. When cells were subjected to
proteasome inhibitors MG-132 or clasto-Lactacystin β-lactone
more mature precursor was seen in the WT GHR relative to
Figure 1. GHR expression in normal and cancerous lung tissue. (a) GHR levels in clinical samples representing 18 SCC and 40 lung
adenocarcinoma analysed from microarray data (GSE10245) retrieved from Gene Expression Omnibus (GEO).24 A signiﬁcant correlation was
determined at P= 0.003. Gene expression analysis of four genes (b) GHR, (c) EGFR, (d) SOCS2 and (e) SOCS3 in 60 clinical samples of normal lung
tissue and NSCLC from a non-smoking female cohort in accordance with microarray data (GSE19804).25 A signiﬁcant difference was observed
(Po0.0001). The expression levels of other genes (SOCS1, CISH and GH2) did not differ signiﬁcantly (Supplementary Figure 1).
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GHRP495T-expressing cells, supporting the more rapid proteaso-
mal degradation of the WT receptor, in accordance with its intact
degron and SOCS-binding site (Figure 6h and Supplementary
Figure 5). In addition, in HEK293 transduced cells expressing WT or
GHRP495T we observed GHR remnants at approximately 60 and
43kDa only in the WT GHR lysates in the absence of hormone,
which may be the result of hormone independent endocytosis/
turnover, possibly through the phospho-degron.37
The GHRP495T increases transcripts associated with tumour
progression
Real-time PCR analysis of BEAS-2B cells transduced to express WT
GHR or GHRP495T following a single 15-min pulse of GH showed
signiﬁcant increases for FOS and EGR1, known GH targets38 at 60-
min post-stimulation (Figure 7a). Moreover, at 120 min after the
initial GH stimulation, a subset of genes associated with
proliferation, epithelial–mesenchymal transition and cancer
metastasis (TWIST1, SNAI2, EGFR, MYC and CCND1) was signiﬁcantly
upregulated only in GHRP495T-expressing cells compared with WT
GHR (Figure 7b). Elevated levels of most of these genes are known
prognostic predictors in patients with NSCLC.39,40 It is also relevant
that GHR signalling strongly induced the expression of epidermal
growth factor receptor (EGFR)41 as observed in BEAS-2B cells
(Figure 7b and Supplementary Figure 6).
DISCUSSION
Two independent studies of different ethnic groups identiﬁed a
SNP in GHR that resulted in the residue change P495T and
increased risk of lung cancer.10,11 We investigated the molecular
basis for how this change may contribute to increased incidence
of lung cancer. Ba/F3 cells expressing GHRP495T showed a
prolonged STAT5 activation following a GH pulse with a higher
residual receptor expression than WT GHR transduced cells and a
signiﬁcant increase in active STAT5 when normalised to receptor
levels. STAT5 activation has been reported in cancers of the breast,
prostate, lung and leukaemia.1 Constitutively active STAT5
Figure 2. GHRP495T increases proliferation owing to enhanced GH-mediated signalling in pre-B cells. (a) Proliferation assay in Ba/F3 cells
transduced with WT GHR or GHRP495T seeded at 1 × 104 cells/ml in growth medium (devoid of IL-3) containing GH (4.5 nM). Cells were counted
daily by Trypan blue exclusion using haemocytometer over a 5-day period. Data presented as mean± s.e.m. analysed by two-way ANOVA
(****Po0.0001, **Po0.01, *Po0.05) and representative of three independent experiments performed in duplicate and conﬁrmed in three
independently transduced cell lines. (b) Time course analysis of GHR-mediated signalling in Ba/F3 cells transduced with WT GHR or GHRP495T.
Serum-starved cells were subjected to an acute GH (2.3 nM) dose for 15 min and harvested at the indicated time points. Cell lysates were
immunoblotted for P-STAT5 (Tyr694/699), total STAT5 and GHR (HA-tag) across all time points and the expression was compared with
β-TUBULIN (loading control). (c) P-STAT5 (Tyr694/699) signal intensity represented as fold change with respect to WT GHR at all time points
and normalised to β-TUBULIN and total GHR (HA-tag) levels. Data presented as mean± s.e.m. analysed by two-way ANOVA (****Po0.0001,
**Po0.01) and representative of three independent experiments conﬁrmed in cell lines ﬂuorescence-activated cell sorted (FACS) for similar
surface GHR expression.
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Figure 3. GHRP495T enhances GH-mediated signalling in a normal lung cell line. (a) BrdU incorporation assay in BEAS-2B cells transduced with
WT GHR and GHRP495T grown on coverslips in growth medium supplemented with GH (4.5 nM) over 24 and 48 h. Cells were treated with
20 μM BrdU and subjected to immunoﬂuorescence. Graphs represent percentage of BrdU-positive cells relative to total number of cells (DAPI)
counted in random ﬁelds of view. Data presented as mean± s.e.m. analysed by Student’s t-test (**Po0.01) and representative of three
independent experiments performed in two independently transduced lines. (b) Time course analysis of GHR-mediated signalling in BEAS-2B
cells transduced with WT GHR and GHRP495T. Serum-starved cells were subjected to acute GH (2.3 nM) dose for 15 min and harvested at the
indicated time points. Cell lysates were immunoblotted for P-AKT (Ser473 and Thr308), total AKT and GHR (HA-tag) (mature (m) receptor and
precursor (p) receptor) across all the time points and compared with β-TUBULIN (loading control). (c) P-AKT (Thr308) signal intensity is
represented as fold change with respect to WT GHR at all time points and normalised to β-TUBULIN levels. (d) BEAS-2B lysates as above
immunoblotted against P-STAT3 (Tyr705) and GHR (HA-tag) (mature (m) receptor and precursor (p) receptor) compared with GAPDH (loading
control). (e) P-STAT3 (Tyr705) signal intensity is represented as fold change with respect to WT GHR at all time points and normalised to total
STAT3 levels. Data presented as mean± s.e.m. analysed by two-way ANOVA (***Po0.001, **Po0.01, *Po0.05) and representative of three
independent experiments conﬁrmed in three separate lines generated by independent transductions.
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transgenic mice show a 22% increased incidence of developing
mammary tumours.42 STAT5 has been shown to induce produc-
tion of reactive oxygen species and DNA damage, which are
important for cancer initiation.43 In BEAS-2B cells, expressing
either WT GHR or GHRP495T, weak STAT5 activation was evident
but not signiﬁcantly different following a GH pulse (data not
shown). However, a signiﬁcant increase in active AKT (pT308) and
STAT3 levels compared with WT was observed, together with
sustained surface GHR. Importantly, the increase in GHR levels was
exacerbated following a second GH pulse indicating that GH-
induced degradation is impaired in GHRP495T, in line with
impairment of a phospho-degron involving T494-P495 as
described below. It has been shown that pT308 active AKT is a
better prognostic indicator for NSCLC than phosphorylated-
S473.31
HEK293 cells stably expressing WT GHR or GHRP495T and
overexpressing SOCS2 showed signiﬁcantly decreased SOCS2
binding to GHRP495T after GH stimulation. This may stem from
the steric hindrance combined with a potential altered phosphor-
ylation pattern, and can explain the increase in STAT5 and AKT
signals observed in the variant as a result of delayed degradation.
Both CISH and SOCS2 are expressed in wide range of tissues with
highest expression in lung, liver, heart and skeletal muscle.44 We
investigated the interaction of GHR with CISH as this is predicted
to bind to GHR-pY487 and -pY595. We could not detect any direct
interaction between GHR with CISH, despite being reported in rat
adipocytes.45 CISH may depend on another protein for binding to
GHR potentially absent in HEK293 cells, or the interaction between
the disordered GHR and CISH may be too transient for co-IP
detection or require other post-translational modiﬁcations. Our
data from hepatic tissues from WT and ghr-/- mice support that
SOCS2 binds and regulates degradation of GHR, whereas CISH
does not. This data showed that although socs2 and cish transcript
levels are dependent on GHR function, CISH protein did not
change between WT and ghr-/-, but SOCS2 accumulated to high
protein levels in the absence of GHR implying that SOCS2 binding
to GHR led to its degradation, potentially exploiting the degron as
suggested below. SOCS2 has been shown to have a major role in
growth, as socs2 is the only socsmember where knockout mice are
giants, whereas cish-/- are not reported to have any growth
Figure 4. GHRP495T impairs SOCS2 binding to GHR. (a) No difference in SOCS2 transcript induction between WT GHR and GHRP495T. HEK293
cells transduced with WT GHR and GHRP495T were maintained in serum-starved media with sustained GH (2.3 nM) then RNA was extracted at
indicated time points. SOCS2 levels were determined by real-time PCR and normalised to GAPDH reference gene. Data presented as mean±
s.e.m. analysed by one-way ANOVA (****Po0.0001, ***Po0.001). Representative of three independent experiments conﬁrmed in three
separate lines generated by independent transductions. (b) HEK293 cells stably expressing WT GHR or GHRP495T, and parental cells
transfected with SOCS2 expression plasmid for 24 h and serum-starved overnight before 2.3 nM GH (+) or vehicle (−) stimulation for 15 min.
Lysates were harvested and co-IP with SOCS2 antibody as described in Materials and methods. Protein complex from the immunoprecipitates
were immunoblotted (IB) using anti-HA antibody for GHR (mature (m) receptor and precursor (p) receptor) and anti-SOCS2 (input). As control,
parental cell line with no transduced GHR was used and a small volume of total cell lysates used for co-IP was probed for GHR levels (HA-tag)
to indicate GHR levels. (c) Graph represents the signal intensity of total GHR (HA-tag) pull down in GHRP495T relative to WT GHR relative to
SOCS2 input, corrected for endogenous GHR expression. Data presented as mean± s.e.m. analysed by Student’s t-test (***Po0.001) and
representative of nine independent experiments conﬁrmed in three independently transduced cell lines. (d) CISH protein does not interact
directly with GHR as compared with SOCS2. HEK293 cells stably expressing WT GHR co-transfected with CISH or SOCS2 expression plasmids for
24 h and serum-starved overnight before 2.3 nM GH (+) or vehicle (-) stimulation for 15 min. Lysates were harvested and co-IP with SOCS2 and
CISH antibodies simultaneously. Protein complex from the immunoprecipitates was immunoblotted using anti-HA antibody (for GHR)
and anti-SOCS2 and anti-CISH antibodies. As a control, parental cell line with no transduced GHR, but transfected with CISH was used and a
small volume of total cell lysates used for co-IP was probed for GHR levels (HA-tag) to indicate endogenous GHR levels (see Supplementary
Figure 2).
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effects.20,46,47 In addition, idiopathic short stature patients express
high levels of SOCS2 transcripts under basal condition compared
with controls.48 Low SOCS2 and SOCS3 transcript levels have been
reported in lung adenocarcinoma patients.49
To conﬁrm that increased signalling in GHRP495T cells is a
surface phenomenon, we pre-treated cells with BFA before GH
stimulation and found a signiﬁcant decrease in mature WT
receptor on the cell surface compared with GHRP495T and the
increase in GHRP495T level was maintained throughout the time
course analysis. The rate of WT GHR degradation was considerably
increased in the presence of SOCS2 with almost undetectable
surface GHR after 30 min.
We investigated the structural changes induced by P495T in
GHR using nuclear magnetic resonance analysis of a portion of the
GHR intracellular region. Comparison between WT GHR and
GHRP495T indicated an altered structural ensemble and the
region around P495T more helical. This potentially affects the
binding region for kinases, SOCS2, and others such as FBW7, and is
evidently sufﬁcient to cause a phenotypic effect in GHRP495T
heterozygous patients, also signiﬁcantly more susceptible to lung
Figure 5. GHRP495T generates structural changes in the receptor intracellular domain. (a) Clustal Omega multiple sequence alignment of the
GHR polypeptide in close proximity to Pro 495 (red). The Tyr residue, a known active STAT5 binding site is coloured blue. Symbols below
indicates (*) identical residues, (:) conservation of strongly similar properties and (.) conservation of weakly similar properties. (b) Importance
of residues surrounding Pro495 to SOCS2 binding. HEK293 cells stably transduced with WT GHR, GHRP495T, GHRP495K, GHRP495A and
GHRT494A were subjected to co-IP analysis as described in Materials and methods. Protein complexes from the immunoprecipitates were
immunoblotted for GHR (anti-HA-tag) (mature (m) receptor and precursor (p) receptor) and SOCS2. As control, a small volume of total cell
lysates used for co-IP was probed to indicate endogenous levels of GHR, SOCS2, and GAPDH (loading control). (c) Graph represents the signal
intensity of total GHR (HA-tag) pull down relative to SOCS2 input, corrected for endogenous GHR expression. Data presented as mean± s.e.m.
analysed by one-way ANOVA (***Po0.001) and representative of three independent experiments conﬁrmed in three lines generated by
independent transductions. (d) GHRP495T changes the structural ensemble in the GHR intracellular domain by nuclear magnetic resonance
spectroscopy analysis. Secondary Cα-chemical shift (SCS) of GHR ICD455-588
WT (top panel). Consecutive positive SCS-values indicate transiently
folded helices (TH) marked in grey boxes. The original TH5, as previously reported34 was re-evaluated as two interrupted transient helices as
TH5.1 (E462-L475), TH5.2 (P478-S488), and are shown together with TH6 and TH7 (top panel). SCS of GHR ICD455-588
P495T (middle panel). P495T
induces helicity around the mutation site and before in the C-terminal of TH5.2. Numbering includes the signal peptide. Model illustrating the
change in structural ensemble around T495 (bottom panel) and the inter-conversion equilibrium between disordered and helical structures,
where the helicity is increased in the GHR ICD455-588
P495T .
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Figure 6. GHRP495T degradation is impaired. (a) Effect of BFA treatment on WT GHR and GHRP495T. Time course analysis on HEK293 cells
transduced with WT GHR and GHRP495T subjected to 2.3 nM GH stimulation for 15 min in the presence of BFA and harvested at indicated time
points. Immunoblot demonstrating GHR (HA-tag) levels (mature (m) receptor and precursor (p) receptor) and β-TUBULIN (loading control).
(b) Graph indicating fold change in mature GHR levels normalised to β-TUBULIN relative to ‘0 min’ time point after GH removal. (c) Immunoblot
indicating GHR (HA-tag) following BFA treatment, as above (a) in the presence of SOCS2. (d) Graph indicating fold change in mature GHR levels in
the presence of SOCS2, normalised to β-TUBULIN relative to ‘0 min’ time point after GH removal. (b, d) Data presented as mean± s.e.m. analysed
by two-way ANOVA (**Po0.01, *Po0.05) and representative of at least three independent experiments conﬁrmed in two independently
transduced lines (see Supplementary Figure 3); (e) GHRP495T is less amenable to degradation owing to SOCS2 as evident from TIRF microscopy
(allows detection of ﬂuorescent proteins only at, or near the cell membrane) images of HEK293 cells transduced with WT GHR-GFP and
GHRP495T-GFP transfected with SOCS2-mCherry in the absence of exogenous GH. Colocalisation (yellow) of SOCS2 (red) and receptor (green)
was more pronounced in GHRP495T (See Supplementary Figure 4). Separate channel images shown below. (f) GHR levels on cell surface of
HEK293 cells expressed as normalised ﬂuorescent intensity in the presence or absence of SOCS2. Data presented as mean± s.e.m. from 30 cells
per condition across two independently transduced cell lines and analysed by one-way ANOVA (**Po0.01) relative to WT GHR-GFP no SOCS2.
Student’s t-test (#Po0.05) between WT GHR-GFP + SOCS2 and GHRP495T-GFP + SOCS2. (g) SOCS2 levels at the cell surface expressed as
normalised ﬂuorescent intensity for the cells analysed above. Data presented as mean± s.e.m. from 30 cells per condition from three
independent experiments across two independently transduced lines and analysed by Student’s t-test (ns, not signiﬁcant). (h) HEK293 cells
transduced with WT GHR and GHRP495T treated with proteasomal inhibitor MG-132 (10 μM) for 2 h before GH (2.3 nM) addition for 15 min.
Immunoblot indicating GHR (HA-tag) levels with mature and precursor receptor and two remnant bands observed at ~ 60 and ~43 kDa only in
WT GHR lysates and undetectable in GHRP495T (see Supplementary Figure 5). Blot representative of four independent experiments.
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Figure 7. GHRP495T increases transcripts associated with tumour progression. BEAS-2B cells transduced with WT GHR and GHRP495T
stimulated with GH (2.3 nM) for 15 min, then RNA was harvested at 60 (a) and 120 min (b) post-initial treatment. (a) Transcript levels of early
GH-response genes c-FOS, EGR1, JUN at 60 min in WT GHR and GHRP495T cells normalised to B2M. (b) Transcript levels of genes associated with
epithelial–mesenchymal transition (EMT) (TWIST1, SNAI2 and TGFB1), proliferation (CCND1, MYC), and elevated GHR signalling (GHR, EGFR, SOCS2
and SOCS3) at 120 min in WT GHR and GHRP495T cells normalised to B2M (see Supplementary Figure 6). Data presented as mean± s.e.m.
analysed by one-way ANOVA (***Po0.001, **Po0.01, *Po0.05) and representative of three independent experiments conﬁrmed in three
independently transduced lines.
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cancer.11 Prolactin receptor degradation is regulated by serine
phosphorylation where glycogen synthase kinase-3β phosphor-
ylation of prolactin receptor S349 is required for recognition by
βTrCP and subsequent ubiquitylation and degradation.50,51
Studies on GHR have only focused on tyrosine phosphorylation,
however, serine and threonine residues comprise 9% and 6%,
respectively, of GHR, whereas tyrosine makes up only 2.8%. It is
currently unknown if any of these serine and threonine residues
are phosphorylated or what kinases may be involved. The
eukaryotic linear motif (ELM) database (www.elm.eu.org) predicts
T494 as a target for glycogen synthase kinase-3, cyclin dependent
kinase 1 or mitogen activated protein kinase, as well as T494-P495
being parts of a phospho-degron (TPxxxS) recognised by the
ubiquitin ligase FBW7.52,53 Thus, the sequence properties around
P495 constitute a phospho-degron motif. Our co-IP data
suggested T494 to be important for SOCS2 binding and it could
be speculated that phosphorylation of T494 may facilitate SOCS2
binding to GHR. Therefore, besides the change in structure, the
new threonine in GHRP495T may potentially become phosphory-
lated or hinder the phosphorylation of T494 resulting in further
impaired SOCS2 or FBW7 binding; a protein also requiring
extended, disordered structure for binding.52
It has been reported that overexpressed or constitutively active
EGFRs are major drivers in lung cancer as their expression
supports survival, proliferation and metastases, hence protection
from cytotoxic agents and radiation therapies.54 In addition, the
EGFR-STAT3 signalling axis promotes tumour survival in NSCLC.55
Given the ability of GH to induce EGFR signalling, together with
STAT3 and AKT activation, the pulsatile manner of GH secretion
(particularly in males, the more lung cancer susceptible sex11), the
extension of GH signalling in GHRP495T appears highly relevant to
its ability to promote lung cancer progression in individuals
particularly those with smoking-induced lung cancers. We expect
that the prolonged downstream GHR signalling is acting as a
promoter in response to DNA damage caused by the inhaled
smoke, particularly the reactive oxygen species component.56
This study highlights the ﬁrst identiﬁed cancer associated
variant of GHR and shows that the P495T variant prolongs
signalling in cell lines associated with reduced degradation of the
GHR. This reduction can occur in a GH-dependent manner
because of decreased SOCS2 binding or in the absence of GH
by alteration of the GHR turnover via modulation of a phospho-
degron. Future research using an animal model carrying the
variant allele is warranted and can shed light on the role of
GHRP495T in tumour initiation or promotion. It is currently
unknown if GHRP495T polymorphism is associated with other
cancer types and if the cancer susceptibility will be tissue speciﬁc,
which will likely depend on the abundance of signal activators and
suppressors. Nevertheless, GHRP495T represents a novel candi-
date SNP that has not been covered on the SNP arrays of recent
GWASs for assessing lung cancer risk, but clearly should be
included.
MATERIALS AND METHODS
Expression vectors
WT human GHR with an introduced N-terminal haemagglutinin (HA)-tag
following the signal peptide was ampliﬁed by PCR with attB adapted
primers from a previously described clone in pCDNA3.157 and Gateway
cloned into pQCXP CMV/TO DEST58 (a gift from Eric Campeau; Addgene,
Cambridge, MA, USA; #17386) and pMX-GW-IRES-Puro. Primers for
generation of the GHR mutations P495T, P495A, P495K and T494A were
created essentially as described59 and cloned into the same destinations
vectors as for WT GHR. pMX-GH-IRES-Puro was created from pMX-IRES-
GFP60 by replacing the stuffer fragment with attR ﬂanked ccdB-CmR, and
replacing GFP with PuroR. C-terminal GFP-tagged constructs were created
by overlap extension PCR. Primer sequences are available on request.
SOCS2 expression plasmid pCMV-SOCS2-Flag was purchased from Origene
(Rockville, MD, USA) and CISH expression plasmid was a kind gift from Dr
Patrick Lau (IMB, The University of Queensland).
Cell culture, transfection analysis and treatments
Ba/F3 cells (kindly provided by Dr Andrew J Hapel, Australian National
University, Canberra, Australia) were cultured in RPMI 1640 medium (Gibco,
Thermo Fisher Scientiﬁc, Scoresby, VIC, Australia) supplemented with 2 mM
L-glutamine, 10% Serum Supreme (Lonza, Tullamarine, VIC, Australia), 100
units/ml interleukin-3 (IL-3). Cells were starved by removing IL-3 or GH and
reducing serum to 0.5% by washing in phosphate-buffered saline (PBS)
and culturing in fresh media as above except containing 0.5% foetal
bovine serum and no IL-3.
HEK293 (ATCC CRL-1573), Plat-E (kindly provided by Professor T
Kitamura, Tokyo University, Tokyo, Japan),61 and 293T (ATCC CRL-3216)
cell lines were cultured in Dulbecco’s modiﬁed Eagle’s medium with 10%
foetal bovine serum. HEK293 cells were starved by washing in PBS and
culturing in Dulbecco’s modiﬁed Eagle’s medium with 0.5% foetal bovine
serum for 16 h. BEAS-2B (Cell Bank Australia, Westmead, NSW, Australia;
95102433) cells were maintained in complete LHC-9 medium (Gibco,
Thermo Fisher Scientiﬁc). Flasks were precoated with 0.01 mg/ml
ﬁbronectin (Becton Dickinson, North Ryde, NSW, Australia), 0.03 mg/ml
collagen (Sigma-Aldrich, St Louis, MO, USA) and 1 μg/ml bovine serum
albumin as described by Cell Bank Australia. BEAS-2B cells were starved in
RPMI-1640 supplemented with 2 mM L-glutamine and 0.5% bovine serum
albumin medium overnight. All cells were maintained in 5% CO2 incubator
at 37 °C. All cell lines were routinely tested for mycoplasma and conﬁrmed
as negative.
Transfections were carried out using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s protocol. Inhibitors BFA,
DAPT, MG-132 (Z-Leu-Leu-Leu-al), clasto-Lactacystin β-lactone were
obtained from Sigma-Aldrich. hGH was expressed and puriﬁed as
described.62
Retroviral transduction
Ba/F3 cells were transduced to stably express WT or GHRP495T by
ecotropic retroviruses produced by transfection of Plat-E cells with GHR
genes cloned in pMX-GW-IRES-Puro essentially as described.57 Cells were
selected with puromycin and total GHR levels were determined by
immunoblotting against N-terminal HA-tag (clone161B2, Covance,
Princeton, NJ, USA). Cells were sorted by ﬂuorescence-activated cell
sorting for similar levels of surface GHR by the HA-tag as described.29
BEAS-2B and HEK293 were transduced to express WT or mutant GHR by
pantropic retroviruses produced by transfection of 293T cells with GHR
genes cloned in pQCXP CMV/TO DEST58 and retroviral packaging vectors
pVPack-GP and pVPack-VSV-G (Stratagene, La Jolla, CA, USA) with
Lipofectamine 2000 and virus was harvested according to the manufac-
turer’s instructions (Stratagene). Transduced cells were selected by
puromycin and GHR expression was determined by immunoblotting.
Quantitative RT–PCR
HEK293 and BEAS-2B transduced cell lines were stimulated with GH as
indicated, and RNA extracted with TRIzol. Similarly, murine hepatic tissue
was homogenised in TRIzol (Life Technologies, Mulgrave, VIC, Australia)
and RNA was extracted as per the manufacturer’s guidelines. Comple-
mentary DNA was synthesised using iScript RT Supermix (Bio-Rad,
Gladesville, NSW, Australia) and transcripts levels quantiﬁed using Sybr
Green Mix (Thermo Fisher Scientiﬁc) on a ViiA7 machine (Applied
Biosystems, Thermo Fisher Scientiﬁc). Analysis was performed by calculat-
ing the change in Ct value between the gene of interest against the
housekeeping gene, β-2 microglobulin (B2M) or GAPDH and represented as
relative levels. Primers used are listed in Supplementary Table 1.
Proliferation assay
Ba/F3 cells transduced with WT and GHRP495T were starved overnight and
seeded at a cell density of 1 × 104 cells/ml duplicate in growth media
supplemented with GH at 4.5 nM instead of IL-3 (day 0). Cells were counted
daily by Trypan blue exclusion using a hemocytometer. Proliferation in
BEAS-2B was measured by BrdU incorporation. Brieﬂy, cells were grown on
coverslips at equal seeding densities and serum starved the following day
to induce cell cycle synchronisation. Cells were then treated with GH at
4.5 nM for 24 and 48 h. Before ﬁxing, cells were given 20 μM 5-bromo-2′-
deoxyuridine (BrdU, Sigma-Aldrich) for 1 h. Cells were washed with PBS
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and ﬁxed in 70% ethanol and coverslips were stained with BrdU antibody
(#5292, Cell Signaling, Danvers, MA, USA) as per the manufacturer’s
guidelines, followed by Alexa Fluor-488 antibody and counterstained with
10 μg/ml 4,6-diamidino-2-phenylindole (DAPI). Random ﬁelds of views
were ﬁrst imaged for DAPI and the same ﬁeld of view was imaged for BrdU
and quantiﬁed blind. Data are represented as percentage of BrdU-
positive cells.
GH signalling analysis and western blotting
Cells were serum-starved overnight and stimulated with 2.3 nM GH in
starve medium for 15 min. GH was removed by two PBS washes and cells
were maintained in starve medium at 37 °C until harvested (by scraping for
adherent cell lines) at subsequent time points as described in the results
section. For BFA experiments, starved cells were pre-treated with 1 μg/ml
BFA for 1 h before GH treatment and BFA was maintained when media was
replaced. At subsequent time points, cells were washed in cold PBS and
subjected to protein extraction in cold RIPA buffer (150 mM NaCl, 50 mM
Tris pH 7.5; 0.5% sodium dodecyl sulphate (SDS), 1% NP-40, sodium
deoxycholate supplemented with protease inhibitors (Roche, Sydney, NSW,
Australia, EDTA-free), 10 mM NaF, 1 mM Na4O7P2, 2 mM Na3VO4) as
described previously.57 Hepatic tissue from WT and ghr-/- mice63 were
homogenised in cold RIPA buffer. Protein concentration was determined
by BCA protein assay kit (Thermo Fisher Scientiﬁc). Equal amount of
protein was boiled in sample buffer (15 mM Tris-HCl (pH6.8), 2% SDS, 10%
glycerol, 10 mM DTT) at for 5 min and resolved on SDS–polyacrylamide gel
electrophoresis gels with transfer to polyvinylidene diﬂuoride and
immunoblotted as described previously using P-STAT5 (Tyr694/Tyr699)
(#4322, Cell Signaling), STAT5 (#sc-835, Santa Cruz Biotechnology, Dallas,
TX, USA), P-AKT (Thr308) (#13038, Cell Signaling), P-AKT (Ser473) (#4060,
Cell Signaling), AKT (#9272, Cell Signaling), GAPDH (#2118, Cell Signaling),
β-TUBULIN (#2128, Cell Signaling), P-STAT3 (Tyr705) (#9145, Cell Signaling)
and STAT3 (#4904, Cell Signaling).57
Co-immunoprecipitation
Transduced HEK293 cells were transfected with 2 μg of CISH or SOCS2
expression plasmid for 24 h. Cells were starved overnight before GH
stimulation (2.3 nM) for 15 min. Cells were harvested in immunoprecipita-
tion buffer containing 150 mM NaCl, 50 mM Tris pH 7.5, 5 mM EDTA, 0.5%
Triton X-100 and supplemented with 100 mM NaF, 2 mM Na3VO4, complete
EDTA-free protease inhibitor cocktail (Roche) and 1 mM phenylmethylsul-
fonyl ﬂuoride. Cell lysates were equalised based on total protein
(determined by BCA assay) then ﬁrst pre-cleared and subsequently
subjected to CISH (#8731, Cell Signaling) or SOCS2 antibody (#2779, Cell
Signaling) pull down for 2 h at 4 °C on a rotating wheel and Protein A/G
sepharose beads (GE Life Science, Parramatta, NSW, Australia) were added
for another 2 h at 4 °C. Beads were washed in the immunoprecipitation
buffer for ﬁve times and boiled in sample buffer (15 mM Tris-HCl (pH6.8),
2% SDS, 10% glycerol, 10 mM DTT) for 5 min. The supernatant was resolved
by SDS–polyacrylamide gel electrophoresis.
Total internal reﬂection ﬂuorescence microscopy
HEK293 cells transduced with WT GHR or GHRP495T (GFP-tagged) were
seeded on glass-bottom culture dishes (MatTek Corporation, Ashland, MA,
USA) and transfected with SOCS2-mCherry 24 h before visualisation on a
TIRF microscope (Marianas, SDC EverestTM, Intelligent Imaging Innovations
Inc., Denver, CO, USA) ﬁtted with a 100x oil immersion objective (NA=1.46,
Carl Zeiss, Jena, Germany) using EMCCD cameras (QuantEM 512sc)
and Slidebook software version 5.5 (3i Inc., Denver, CO, USA). Cells were
imaged in live-cell imaging medium (Thermo Fisher Scientiﬁc) and analysis
performed as previously described.64
Nuclear magnetic resonance
WT residues GHR-ICDI455-S588/GHR-ICDI436-S570 (numbers ± signal peptide)
and with the variant P495T (or P477T) GHR-ICDI455-S588
P495T , were cloned into
the pGEX-4T1 vector as a GST fusion separated by a TEV-cleavage site. The
recombinant proteins were expressed in Escherichia coli BL21(DE3) in
15N,13C minimal media and puriﬁed as described.34 Backbone chemical
shifts were assigned from similar sets of nuclear magnetic resonance
spectra as in Haxholm et al.34 for both proteins in 20 mM Na2HPO4/
NaH2PO4 and in 8 M urea at pH 7.3, respectively. Samples of 350 μl were
added 10% (v/v) 2H2O, 5–8 mM tris(2-carboxyethyl)phosphine and 0.5 mM
2,2-dimethyl-2-silapentane-5-sulphonic acid for referencing. Transient
secondary structures were identiﬁed from secondary chemical shifts
calculated by subtracting the δCα for each residue in 7–8 M urea from those
in 20 mM Na2HPO4/NaH2PO4. The population of transient α-helices (THs)
was assessed as previously described.65
Bioinformatics analysis
Multiple sequence alignment of GHR was carried out on protein sequences
sourced from NCBI database using Clustal Omega tool (http://www.ebi.ac.
uk/Tools/msa/clustalo/).66
Microarray expression data were from the NCBI GEO DataSet database
(http://www.ncbi.nlm.nih.gov/gds).67 Array proﬁling for GHR levels was
performed on 18 SCC and 40 lung adenocarcinoma tissues data set
(GSE10245)24 and represented as dot plot. Individual data points for
relative expression of numerous genes expressed in paired clinical samples
representing 60 normal lung tissue and 60 NSCLC tumours derived from
non-smoking females (GSE19804)25 was performed and plotted as
mean± s.e.m. Data for NSCLC shown are only for female cohorts as no
GeoDATA set was available for NSCLC for the male sub-population. This
analysis was carried out to indicate the increase in GHR and decrease in
SOCS2 levels in the available NSCLC cohort. Data were analysed using
Student’s t-test.
Statistical analysis
Densitometric quantitation was performed on immunoblots using ImageJ
software (NIH, Bethesda, MD, USA). Values were normalised to β-TUBULIN
or GAPDH and represented as arbitrary units. Statistical analyses were
performed using GraphPad-PRISM software (La Jolla, CA, USA) based on a
minimum of three independent experiments using Student’s t-test for
comparison between two groups or one-way analysis of variance (ANOVA)
test followed by a Tukey’s post-test for analysing means at one variable or
two-way ANOVA followed by a Bonferroni post-test for analysing means at
two independent variables. Signiﬁcance was scored as: ****Po0.0001;
***Po0.001; **Po0.01; *Po0.05.
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